
Basic Genomics
Pioneering single-cell genomics with cost-efficient RNA isoform analysis for health and disease research.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
investor | €0.0 | round | |
* | $1.2m | Seed | |
Total Funding | 000k |
SEK | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 |
% growth | - | - | (49 %) | 1906 % |
EBITDA | 0000 | 0000 | 0000 | 0000 |
Profit | 0000 | 0000 | 0000 | 0000 |
% profit margin | - | (73 %) | (1355 %) | 13 % |
EV | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Basic Genomics is a technology-driven life science company specializing in the characterization of nucleic acid molecules in single cells. The company operates in the genomics market, focusing on providing a crucial layer in single-cell sequencing by enabling cost-efficient analysis of RNA isoforms. This service is particularly valuable for research in health and disease, offering insights that are not accessible through traditional sequencing methods. Basic Genomics serves researchers and institutions in the life sciences sector, leveraging its expertise to empower scientific discovery. The business model is centered around offering advanced genomic analysis services, generating revenue through partnerships and collaborations with research entities. By addressing a specific need in the genomics field, Basic Genomics positions itself as a key player in advancing single-cell research.
Keywords: genomics, single-cell, RNA isoforms, nucleic acid, life science, sequencing, health, disease, research, analysis